Issue 19, 2017

Gadolinium-based nanoscale MRI contrast agents for tumor imaging

Abstract

Gadolinium-based nanoscale magnetic resonance imaging (MRI) contrast agents (CAs) have gained significant momentum as a promising nanoplatform for detecting tumor tissue in medical diagnosis, due to their favorable capability of enhancing the longitudinal relaxivity (r1) of individual gadolinium ions, delivering to the region of interest a large number of gadolinium ions, and incorporating different functionalities. This mini-review highlights the latest developments and applications, and simultaneously gives some perspectives for their future development.

Graphical abstract: Gadolinium-based nanoscale MRI contrast agents for tumor imaging

Article information

Article type
Review Article
Submitted
08 Feb 2017
Accepted
28 Mar 2017
First published
28 Mar 2017

J. Mater. Chem. B, 2017,5, 3431-3461

Gadolinium-based nanoscale MRI contrast agents for tumor imaging

Y. Cao, L. Xu, Y. Kuang, D. Xiong and R. Pei, J. Mater. Chem. B, 2017, 5, 3431 DOI: 10.1039/C7TB00382J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements